NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

NCT02541955

CompletedPhase 4

Sponsor: Veena Ranganath, MD, MS

Conditions: Rheumatoid Arthritis (RA)

Interventions: Acthar

Countries: United States

This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patient must meet 1987 ACR criteria
2. Age \> 18 years of age
3. Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) \>=3.2
4. Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)
5. Stable prednisone \<10mg or equivalent
6. Power Doppler score of \>=10

Exclusion Criteria:

1. Prior treatment with Acthar in the past 2mos
2. Meet one of the above RA flare requirements
3. Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

Locations (1)

Los Angeles, California, United States